13FPulse 13FPulse
中
More

Explore

Research

AM

AMRX AMNEAL PHARMACEUTICALS INC

2026Q2 · CUSIP 03168L105 · Sector: Healthcare & Biotech

Funds left

Funds are exiting, but the price is holding

Funds that own it
312
Institutions that reported holding it to the SEC
Net decrease in holders
4
Last quarter 316 → now 312
How unusual is that
Bottom 20%
Stronger than only 16% of US stocks
What the filings say, in one paragraph

312 funds held AMRX at the end of 2026Q2, down 4 from the quarter before. Buying has faded, though the price is holding up. On the business itself, revenue over the last 12 months was $3.1B(YoY +9.3%), the P/E is 43.8x, return on equity is 476.5%. AMRX has had 7 buying rushes in its history, and the price moved +17.5% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2018Q3: holders=165 2018Q4: holders=164 2019Q1: holders=159 2019Q2: holders=129 2019Q3: holders=123 2019Q4: holders=130 2020Q1: holders=125 2020Q2: holders=138 2020Q3: holders=139 2020Q4: holders=132 2021Q1: holders=159 2021Q2: holders=159 2021Q3: holders=153 2021Q4: holders=153 2022Q1: holders=167 2022Q2: holders=153 2022Q3: holders=156 2022Q4: holders=157 2023Q1: holders=144 2023Q2: holders=128 2023Q3: holders=143 2023Q4: holders=153 2024Q1: holders=176 2024Q2: holders=182 2024Q3: holders=183 2024Q4: holders=199 2025Q1: holders=238 2025Q2: holders=239 2025Q3: holders=251 2025Q4: holders=279 2026Q1: holders=316 2026Q2: holders=312 -39 -19.5 +0 +19.5 +39 110221332 18Q319Q320Q321Q322Q323Q324Q325Q326Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 7 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q1 Top 10% +52.6% —
2025Q4 Top 20% -16.2% +22.6%
2025Q1 Top 5% +24.4% +54.4%
2024Q1 Top 20% +19.5% +24.2%
2023Q3 Top 20% +32.3% +54.0%
2022Q1 Top 20% -19.5% -35.9%
2021Q1 Top 20% -13.4% -14.1%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
158
Change in large funds
+7
Total value they hold
$2.9B
Funds buying for the first time
49
Funds that sold out entirely
53
Price change that quarter
+54.5%
Funds holding puts (bearish)
0
Funds holding calls (bullish)
3

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

Fundamentals

PE (TTM)
43.8
EPS (TTM)
$0.48
EPS YoY
+4700.0%
Revenue (TTM)
$3.1B
Revenue YoY
+9.3%
Net margin
5.1%
ROE
476.5%
Debt ratio
99.1%
FCF (TTM)
$128M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2024-03-31: EPS -0.30 2024-06-30: EPS 0.02 2024-09-30: EPS 0.00 2024-12-31: EPS -0.10 2025-03-31: EPS 0.04 2025-06-30: EPS 0.07 2025-09-30: EPS 0.01 2025-12-31: EPS 0.10 2026-03-31: EPS 0.19 2026-06-30: EPS 0.18 0M 407M 814M $M -0.33 -0.06 0.21 20182019202020212022202320242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
29 511 992 20252026

P/E = close around day 47 after quarter-end ÷ TTM EPS then; this is a consistent valuation date, not the company’s actual filing date; loss quarters hidden

Quarterly free cash flow
-131M55M240M 2017201820192020202120222023202420252026
Latest quarter $-35M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.